Spero Therapeutics Files 8-K on Financials
Ticker: SPRO · Form: 8-K · Filed: Aug 12, 2025 · CIK: 1701108
| Field | Detail |
|---|---|
| Company | Spero Therapeutics, Inc. (SPRO) |
| Form Type | 8-K |
| Filed Date | Aug 12, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, operations, disclosure
TL;DR
Spero Therapeutics dropped an 8-K on Aug 12th covering financials and operations.
AI Summary
Spero Therapeutics, Inc. filed an 8-K on August 12, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Cambridge, Massachusetts.
Why It Matters
This 8-K filing provides crucial updates on Spero Therapeutics' financial health and operational results, which can impact investor decisions and market perception.
Risk Assessment
Risk Level: low — This filing is a standard current report (8-K) detailing financial information and operational updates, not indicating any immediate or significant new risks.
Key Players & Entities
- Spero Therapeutics, Inc. (company) — Registrant
- August 12, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Cambridge, Massachusetts (location) — Address of principal executive offices
- 675 Massachusetts Avenue, 14th Floor (address) — Principal executive offices
FAQ
What specific financial results are being reported in this 8-K?
The filing indicates it covers 'Results of Operations and Financial Condition' but does not provide specific figures within the provided text.
What is the primary purpose of this 8-K filing for Spero Therapeutics?
The primary purpose is to report on the company's results of operations and financial condition, along with Regulation FD disclosures and financial statements/exhibits.
When was this 8-K filed?
The filing was made on August 12, 2025.
Where are Spero Therapeutics' principal executive offices located?
The principal executive offices are located at 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts, 02139.
What is Spero Therapeutics' standard industrial classification?
Spero Therapeutics' standard industrial classification is 'PHARMACEUTICAL PREPARATIONS [2834]'.
Filing Stats: 690 words · 3 min read · ~2 pages · Grade level 11.3 · Accepted 2025-08-12 16:17:42
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value SPRO The Nasdaq Global Se
Filing Documents
- d97572d8k.htm (8-K) — 28KB
- d97572dex991.htm (EX-99.1) — 54KB
- d97572dex992.htm (EX-99.2) — 27KB
- g97572ex99_2s10g1.jpg (GRAPHIC) — 96KB
- g97572ex99_2s11g1.jpg (GRAPHIC) — 113KB
- g97572ex99_2s12g1.jpg (GRAPHIC) — 104KB
- g97572ex99_2s13g1.jpg (GRAPHIC) — 100KB
- g97572ex99_2s14g1.jpg (GRAPHIC) — 66KB
- g97572ex99_2s15g1.jpg (GRAPHIC) — 98KB
- g97572ex99_2s16g1.jpg (GRAPHIC) — 124KB
- g97572ex99_2s17g1.jpg (GRAPHIC) — 69KB
- g97572ex99_2s18g1.jpg (GRAPHIC) — 82KB
- g97572ex99_2s19g1.jpg (GRAPHIC) — 44KB
- g97572ex99_2s1g1.jpg (GRAPHIC) — 48KB
- g97572ex99_2s2g1.jpg (GRAPHIC) — 207KB
- g97572ex99_2s3g1.jpg (GRAPHIC) — 85KB
- g97572ex99_2s4g1.jpg (GRAPHIC) — 81KB
- g97572ex99_2s5g1.jpg (GRAPHIC) — 63KB
- g97572ex99_2s6g1.jpg (GRAPHIC) — 85KB
- g97572ex99_2s7g1.jpg (GRAPHIC) — 100KB
- g97572ex99_2s8g1.jpg (GRAPHIC) — 110KB
- g97572ex99_2s9g1.jpg (GRAPHIC) — 123KB
- 0001193125-25-178970.txt ( ) — 2721KB
- spro-20250812.xsd (EX-101.SCH) — 3KB
- spro-20250812_lab.xml (EX-101.LAB) — 18KB
- spro-20250812_pre.xml (EX-101.PRE) — 11KB
- d97572d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press release issued by Spero Therapeutics, Inc. on August 12, 2025 99.2 Corporate Investor Presentation of Spero Therapeutics, Inc. as of August 12, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and incorporated as Exhibit 101) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 12, 2025 SPERO THERAPEUTICS, INC. By: /s/ Esther Rajavelu Esther Rajavelu Chief Executive Officer, Chief Financial Officer and Chief Business Officer